Calidi Biotherapeutics stock was up 171.84% in pre-market trading on Wednesday, following a 39.47% rally yesterday. However, ...

Calidi Biotherapeutics Inc. CLDI stock surged by 39.47% in the after-hours trading session on Tuesday. The stock price ...

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today ...

Get the detailed quarterly/annual income statement for Calidi Biotherapeutics, Inc. (CLDI). Find out the revenue, expenses and profit or loss over the last fiscal year.

Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease ...

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its placement in an editorial published by NetworkNewsWire ("NNW ...

Ladenburg Thalmann & Co, Inc. is acting as the exclusive placement agent for the offering.

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company pioneering the development of targeted therapies that can deliver genetic medicines to sites of disease.

Calidi Biotherapeutics Inc. (NYSE American: CLDI) has spent over 10 years developing a groundbreaking platform for the systemic delivery of genetic medicines that can precisely target tumors ...